Menicon opens new contact lens R&D and manufacturing facility in Singapore

NewsGuard 100/100 Score

Menicon Singapore, a subsidiary of Menicon Co., Ltd., Japan's first and largest contact lens manufacturer, has opened its new R&D and manufacturing facility. Located at International Business Park, the 6,000-square-meter facility is the company's first manufacturing facility in the world producing daily disposable contact lenses, and will also house Menicon's first R&D center in Asia outside Japan.

The new US$97 million dollar facility, which will feature quality control systems and unique state-of-the-art manufacturing technology developed by Menicon, was officially opened by Mr. S. Iswaran, Senior Minister of State, Ministry of Trade and Industry and Education, on March 2.

Menicon is dedicated to all areas of the contact lens business including material development, lens design and the manufacture of contact lenses and care solutions. The new facility will expand Menicon's capacity and competitiveness for the supply of daily disposable lenses to global markets.

In addition to producing daily disposable contact lenses, the new facility is slated to become a hub for the development of new technologies, complementing research conducted in Japan. Menicon Singapore will utilize technology developed locally in Singapore to produce state-of-the-art disposable contact lenses.

Speaking at the official opening, Dr. Hidenari Tanaka, CEO, Menicon Co., Ltd., said, "The opening of Menicon Singapore's manufacturing and R&D facility will propel Menicon into a global contact lens manufacturer and strengthen our position as a global vision care company. Singapore's economic and social stability, pro-business policies, competitive production costs, leading-edge medical technology, outstanding human resource capabilities and advanced industrial development were key factors behind our decision to set up this facility as the company forges ahead with global business expansion."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
MD Anderson and CureVac collaborate on mRNA-based cancer vaccines